Geographic Differences in Cannabis Use and Cannabis Use Disorder in the US Veteran Population [0.03%]
美国退伍军人人口中的大麻使用及与大麻相关的障碍的地理差异
Annie-Lori Joseph Denk,Sarah B True,Melanie L Hill et al.
Annie-Lori Joseph Denk et al.
Objective: To examine regional differences in cannabis use and probable cannabis use disorder (CUD) in US veterans. Methods: Participants (N = 2,441) were drawn from a nationally representative sample of US veterans who...
How Many Criteria Should Be Required to Define the DSM-5 Mixed Features Specifier in Depressed Patients? [0.03%]
定义DSM-5抑郁患者混合特征规定需多少标准riteria合适？
Mark Zimmerman,Daniel Mackin
Mark Zimmerman
Background: During the past 2 decades, there has been intense interest in the clinical significance of the concurrence of manic symptoms in depressed patients. DSM-5 introduced a mixed features specifier for both bipolar depression and majo...
Next-Step Treatment Options for Treatment-Resistant Depression: Insights From the Mayo Clinic Depression Center Panel [0.03%]
迈阿密抑郁中心专家组解读难治性抑郁症的下一步治疗方案
Matheus G Marques,Aysegul Özerdem,Simon Kung et al.
Matheus G Marques et al.
Objective: Treatment-resistant depression (TRD) affects one-third of patients with major depressive disorder, leading to increased morbidity, health care costs, and suicide risk. TRD lacks a standardized definition, complicating treatment s...
The Position of Clozapine in Patients With Treatment-Resistant Schizophrenia: Reply to Mattes [0.03%]
氯丙嗪在治疗难治性精神分裂症患者中的地位：回复马特斯评论
Chittaranjan Andrade
Chittaranjan Andrade
Factors Associated With Revisiting the Emergency Department due to Suicidal Behavior in Children and Adolescents [0.03%]
与儿童和青少年因自杀行为再次访问急诊科相关的因素
Ana María de Granda-Beltrán,Inmaculada Peñuelas-Calvo,María Taracena-Cuerda et al.
Ana María de Granda-Beltrán et al.
Objective: Suicide is a major public health concern with a significant global impact. Among children and adolescents, an increasing incidence of suicidal behavior is being observed. Several studies have noted an increase in the number of em...
Jeffrey A Mattes
Jeffrey A Mattes
Ketamine-Associated Uropathy in Therapeutic Contexts: Reply to Abdelrahman [0.03%]
氯胺酮相关性尿路病变的治疗_context_回复_Abdelrahman教授
Chittaranjan Andrade
Chittaranjan Andrade
Asem Abdelrahman
Asem Abdelrahman
Rethinking Amisulpride: Could N-Methylation Result in a New and Even Better Antipsychotic? [0.03%]
甲磺吡托必利：N-甲基化改性能否使其成为更有效的抗精神病药物？
John M Kane,Christoph U Correll
John M Kane
Innovation in Psychiatric Drug Development: A Quantitative Analysis of FDA-Approved Psychiatric Drugs, 2012-2024 [0.03%]
2012年至2024年FDA批准的精神病药物的定量分析及精神病药物开发中的创新
John Havlik,Sayana Isaac,Caitlin Radovan et al.
John Havlik et al.
Objective: Psychiatric drug development is critical for addressing the global burden of mental illness, but the degree of recent innovation is not well understood. Prior studies have highlighted concerns over the stagnation of new therapeut...
Observational Study
The Journal of clinical psychiatry. 2026 Jan 12;87(1):25m16063. DOI:10.4088/JCP.25m16063 2026